Advertisement

Angiogenesis and Lung Cancer

  • Dietmar W. Siemann
  • Susan M. Galbraith
  • Wenyin Shi
Part of the Medical Radiology Radiation Oncology book series (MEDRAD)

Keywords

Vascular Endothelial Growth Factor Vascular Endothelial Growth Factor Level Antiangiogenic Therapy Small Cell Lung Carcinoma Vascular Endothelial Growth Factor Pathway 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Akhter S, Nath SK, Tse CM, Williams J, Zasloff M, Donowitz M (1999) Squalamine, a novel cationic steroid, specifically inhibits the brush-border Na+/H+ exchanger isoform NHE3. Am J Physiol 276:C136–C144PubMedGoogle Scholar
  2. Altorki NK, Keresztes RS, Port JL (2002) Celecoxib (Celebrex), a selective COX-2 inhibitor, enhances the response to preoperative paclitaxel/carboplatin in early stage non-small cell lung cancer. Proc ASCO 21, 26a, abstractGoogle Scholar
  3. American Cancer Society (2003) Cancer facts and figures 2003. American Cancer Society, Atlanta, GeorgiaGoogle Scholar
  4. Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM (2003) Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 21:2823–2830CrossRefPubMedGoogle Scholar
  5. Angeletti CA, Lucchi M, Fontanini G, Mussi A, Chella A, Ribechini A, Vignati S, Bevilacqua G (1996) Prognostic significance of tumoral angiogenesis in completely resected late stage lung carcinoma (stage IIIA-N2). Impact of adjuvant therapies in a subset of patients at high risk of recurrence. Cancer 78:409–415CrossRefPubMedGoogle Scholar
  6. Apolinario RM, van der Valk, de Jong JS, Deville W, Ark-Otte J, Dingemans AM, van Mourik JC, Postmus PE, Pinedo HM, Giaccone G (1997) Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J Clin Oncol 15:2456–2466PubMedGoogle Scholar
  7. Baguley BC (2003) Antivascular therapy of cancer: DMXAA. Lancet Oncol 4:141–148PubMedGoogle Scholar
  8. Beadsmoore CJ, Screaton NJ (2003) Classification, staging and prognosis of lung cancer. Eur J Radiol 45:8–17CrossRefPubMedGoogle Scholar
  9. Beauregard DA, Thelwall PE, Chaplin DJ, Hill SA, Adams GE, Brindle KM (1998) Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status. Br J Cancer 77:1761–1767PubMedGoogle Scholar
  10. Beinert T, Binder D, Oehm C, Ziemer S, Priem F, Schweigert M, Stuschke M, Fleischhacker M, Siebert G, Mergenthaler HG, Werner TG, Sezer O, Possinger K (1999) Increased levels of vascular endothelial growth factor in bronchoalveolar lavage of patients with bronchial carcinoma effect of tumour activity and oxidative stress due to radio-chemotherapy? Eur J Med Res 4:328–334PubMedGoogle Scholar
  11. Berger W, Setinek U, Mohr T, Kindas-Mugge I, Vetterlein M, Dekan G, Eckersberger F, Caldas C, Micksche M (1999) Evidence for a role of FGF-2 and FGF receptors in the proliferation of non-small cell lung cancer cells. Int J Cancer 83:415–423CrossRefPubMedGoogle Scholar
  12. Bhargava P, Marshall JL, Dahut W, Rizvi N, Trocky N, Williams JI, Hait H, Song S, Holroyd KJ, Hawkins MJ (2001) A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers. Clin Cancer Res 7:3912–3919PubMedGoogle Scholar
  13. Blavier L, Henriet P, Imren S, Declerck YA (1999) Tissue inhibitors of matrix metalloproteinases in cancer. Ann NY Acad Sci 878:108–119PubMedGoogle Scholar
  14. Boehle AS, Sipos B, Kliche U, Kalthoff H, Dohrmann P (2001) Combretastatin A-4 prodrug inhibits growth of human non-small cell lung cancer in a murine xenotransplant model. Ann Thorac Surg 71:1657–1665PubMedGoogle Scholar
  15. Bono AV, Celato N, Cova V, Salvadore M, Chinetti S, Novario R (2002) Microvessel density in prostate carcinoma. Prostate Cancer Prostatic Dis 5:123–127CrossRefPubMedGoogle Scholar
  16. Brattstrom D, Bergqvist M, Larsson A, Holmertz J, Hesselius P, Rosenberg L, Brodin O, Wagenius G (1998) Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients. Anticancer Res 18:1123–1127PubMedGoogle Scholar
  17. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA (1994) Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157–1164CrossRefPubMedGoogle Scholar
  18. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA (1995) Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 96:1815–1822PubMedGoogle Scholar
  19. Brown PD, Bloxidge RE, Stuart NS, Gatter KC, Carmichael J (1993) Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J Natl Cancer Inst 85:574–578PubMedGoogle Scholar
  20. Bruns CJ, Liu W, Davis DW, Shaheen RM, McConkey DJ, Wilson MR, Bucana CD, Hicklin DJ, Ellis LM (2000) Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer 89:488–499CrossRefPubMedGoogle Scholar
  21. Capillo M, Mancuso P, Gobbi A, Monestiroli S, Pruneri G, Dell'Agnola C, Martinelli G, Shultz L, Bertolini F (2003) Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. Clin Cancer Res 9:377–382PubMedGoogle Scholar
  22. Chandrachud LM, Pendleton N, Chisholm DM, Horan MA, Schor AM (1997) Relationship between vascularity, age and survival in non-small-cell lung cancer. Br J Cancer 76:1367–1375PubMedGoogle Scholar
  23. Cherrington JM, Strawn LM, Shawver LK (2000) New paradigms for the treatment of cancer: the role of anti-angiogenesis agents. Adv Cancer Res 79:1–38PubMedGoogle Scholar
  24. Ching LM, Joseph WR, Crosier KE, Baguley BC (1994) Induction of tumor necrosis factor-alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Cancer Res 54:870–872PubMedGoogle Scholar
  25. Collingridge DR, Carroll VA, Glaser M, Aboagye EO, Osman S, Hutchinson OC, Barthel H, Luthra SK, Brady F, Bicknell R, Price P, Harris AL (2002) The development of ((124)I)iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. Cancer Res 62:5912–5919PubMedGoogle Scholar
  26. Comis RL (2003) A brief history of the research and treatment of lung cancer from 1970 to 200. Int J Clin Oncol 8:230–233CrossRefPubMedGoogle Scholar
  27. Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, Delfino JJ, Siegel NR, Leimgruber RM, Feder J (1989) Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 84:1470–1478PubMedGoogle Scholar
  28. Cox G, Walker RA, Andi A, Steward WP, O'Byrne KJ (2000) Prognostic significance of platelet and microvessel counts in operable non-small cell lung cancer. Lung Cancer 29:169–177CrossRefPubMedGoogle Scholar
  29. D'Amato RJ, Loughnan MS, Flynn E, Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91:4082–4085PubMedGoogle Scholar
  30. Dazzi C, Cariello A, Maioli P, Solaini L, Scarpi E, Rosti G, Lanzanova G, Marangolo M (1999) Prognostic and predictive value of intratumoral microvessels density in operable non-small-cell lung cancer. Lung Cancer 24:81–88CrossRefPubMedGoogle Scholar
  31. de Bazelaire C, Alsop D, Rofsky N, Wang Y, Mietlowski W, Reitsma D, Laurent D, Michaelson D, Kantoff P, George D (2003) MRI-assessed changes in tumor blood flow following treatment with PTK/ZK correlate with subsequent tumor shrinkage or growth in patients with metastatic renal cell carcinoma. Clin Cancer Res 9:[Suppl 16]120Google Scholar
  32. Decaussin M, Sartelet H, Robert C, Moro D, Claraz C, Brambilla C, Brambilla E (1999) Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Fltl and VEGF-R2-Flk 1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival. J Pathol 188:369–377CrossRefPubMedGoogle Scholar
  33. Denekamp J (1990) Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev 9:267–282CrossRefPubMedGoogle Scholar
  34. DeVore R, Fehrenbacher RS, Herbst RS (2000)A randomized Phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with Stage III/IV NSCLC. Proc ASCO 2000 19, 485a, abstractGoogle Scholar
  35. Dickinson AJ, Fox SB, Persad RA, Hollyer J, Sibley GN, Harris AL (1994) Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br J Urol 74:762–766PubMedGoogle Scholar
  36. Downey RJ (1999) Surgical management of lung cancer. J Thorac Imaging 14:266–269PubMedGoogle Scholar
  37. Drevs J (2003) Soluble markers for the detection of hypoxia under antiangiogenic treatment. Anticancer Res 23:1159–1161PubMedGoogle Scholar
  38. Duarte IG, Bufkin BL, Pennington MF, Gal AA, Cohen C, Kosinski AS, Mansour KA, Miller JI (1998) Angiogenesis as a predictor of survival after surgical resection for stage I non-small-cell lung cancer. J Thorac Cardiovasc Surg 115:652–658CrossRefPubMedGoogle Scholar
  39. Eliceiri BP, Cheresh DA (1999) The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest 103:1227–1230PubMedGoogle Scholar
  40. Erdi YE, Macapinlac H, Rosenzweig KE, Humm JL, Larson SM, Erdi AK, Yorke ED (2000) Use of PET to monitor the response of lung cancer to radiation treatment. Eur J Nucl Med 27:861–866CrossRefPubMedGoogle Scholar
  41. Eriksson R, Persson HW, Dymling SO, Lindstrom K (1991) Evaluation of Doppler ultrasound for blood perfusion measurements. Ultrasound Med Biol 17:445–452CrossRefPubMedGoogle Scholar
  42. Fabbro D, Manley PW (2001) Su-6668. SUGEN. Curr Opin Invest Drugs 2:1142–1148Google Scholar
  43. Ferrara N (2002) Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 29:10–14CrossRefGoogle Scholar
  44. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676CrossRefPubMedGoogle Scholar
  45. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186PubMedGoogle Scholar
  46. Folkman J (1975) Tumor angiogenesis: a possible control point in tumor growth. Ann Intern Med 82:96–100PubMedGoogle Scholar
  47. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27–31PubMedGoogle Scholar
  48. Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29:15–18CrossRefGoogle Scholar
  49. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP, McMahon G (1999) SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59:99–106PubMedGoogle Scholar
  50. Fontanini G, Bigini D, Vignati S, Basolo F, Mussi A, Lucchi M, Chine S, Angeletti CA, Harris AL, Bevilacqua G (1995) Microvessel count predicts metastatic disease and survival in non-small cell lung cancer. J Pathol 177:57–63CrossRefPubMedGoogle Scholar
  51. Fontanini G, Lucchi M, Vignati S, Mussi A, Ciardiello F, De Laurentiis M, De Placido S, Basolo F, Angeletti CA, Bevilacqua G (1997) Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J Natl Cancer Inst 89:881–886PubMedGoogle Scholar
  52. Fontanini G, de Laurentiis M, Vignati S, Chine S, Lucchi M, Silvestri V, Mussi A, de Placido S, Tortora G, Bianco AR, Gullick W, Angeletti CA, Bevilacqua G, Ciardiello F (1998) Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res 4:241–249PubMedGoogle Scholar
  53. Fontanini G, Calcinai A, Boldrini L, Lucchi M, Mussi A, Angeletti CA, Cagno C, Tognetti MA, Basolo F (1999) Modulation of neoangiogenesis in bronchial preneoplastic lesions. Oncol Rep 6:813–817PubMedGoogle Scholar
  54. Fontanini G, Faviana P, Lucchi M, Boldrini L, Mussi A, Camacci T, Mariani MA, Angeletti CA, Basolo F, Pingitore R (2002) A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br J Cancer 86:558–563CrossRefPubMedGoogle Scholar
  55. Gadducci A, Viacava P, Cosio S, Fanelli G, Fanucchi A, Cecchetti D, Cristofani R, Genazzani AR (2003) Intratumoral microvessel density, response to chemotherapy and clinical outcome of patients with advanced ovarian carcinoma. Anticancer Res 23:549–556PubMedGoogle Scholar
  56. Galbraith SM, Chaplin DJ, Lee F, Stratford MR, Locke RJ, Vojnovic B, Tozer GM (2001) Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res 21:93–102PubMedGoogle Scholar
  57. Galbraith SM, Lodge MA, Taylor NJ, Rustin GJ, Bentzen S, Stirling JJ, Padhani AR (2002) Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis. NMR Biomed 15:132–142CrossRefPubMedGoogle Scholar
  58. Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ, Stirling JJ, Sena L, Padhani AR, Rustin GJ (2003) Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 21:2831–2842CrossRefPubMedGoogle Scholar
  59. Gerber HP, Dixit V, Ferrara N (1998) Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and Al in vascular endothelial cells. J Biol Chem 273:13313–13316CrossRefPubMedGoogle Scholar
  60. Giatromanolaki A, Koukourakis M, O'Byrne K, Fox S, Whitehouse R, Talbot DC, Harris AL, Gatter KC (1996) Prognostic value of angiogenesis in operable non-small cell lung cancer. J Pathol 179:80–88CrossRefPubMedGoogle Scholar
  61. Gill M, Dias S, Hattori K, Rivera ML, Hicklin D, Witte L, Girardi L, Yurt R, Himel H, Rafii S (2001) Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells. Circ Res 88:167–174PubMedGoogle Scholar
  62. Gingras D, Boivin D, Deckers C, Gendron S, Barthomeuf C, Beliveau R (2003) Neovastat — a novel antiangiogenic drug for cancer therapy. Anticancer Drugs 14:91–96CrossRefPubMedGoogle Scholar
  63. Giuliani R, Bastaki M, Coltrini D, Presta M (1999) Role of endothelial cell extracellular signal-regulated kinase 1/2 in urokinase-type plasminogen activator upregulation and in vitro angiogenesis by fibroblast growth factor-2. J Cell Sci 112 (Pt 15):2597–2606PubMedGoogle Scholar
  64. Gohji K, Fujimoto N, Fujii A, Komiyama T, Okawa J, Nakajima M (1996a) Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinases-2 ratio in recurrence of urothelial cancer after complete resection. Cancer Res 56:3196–3198PubMedGoogle Scholar
  65. Gohji K, Fujimoto N, Komiyama T, Fujii A, Ohkawa J, Kamidono S, Nakajima M (1996b) Elevation of serum levels of matrix metalloproteinase-2 and-3 as new predictors of recurrence in patients with urothelial carcinoma. Cancer 78:2379–2387CrossRefPubMedGoogle Scholar
  66. Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843–850PubMedGoogle Scholar
  67. Goto H, Yano S, Zhang H, Matsumori Y, Ogawa H, Blakey DC, Sone S (2002) Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice. Cancer Res 62:3711–3715PubMedGoogle Scholar
  68. Gridelli C, Maione P, Airoma G, Rossi A (2002) Selective cyclooxygenase-2 inhibitors and non-small cell lung cancer. Curr Med Chem 9:1851–1858CrossRefPubMedGoogle Scholar
  69. Griffiths JR, Taylor NJ, Howe FA, Saunders MI, Robinson SP, Hoskin PJ, Powell ME, Thoumine M, Caine LA, Baddeley H (1997) The response of human tumors to carbogen breathing, monitored by Gradient-Recalled Echo Magnetic Resonance Imaging. Int J Radiat Oncol Biol Phys 39:697–701CrossRefPubMedGoogle Scholar
  70. Griggs J, Brindle KM, Metcalfe JC, Hill SA, Smith GA, Beauregard DA, Hesketh R (2001) Potent anti-metastatic activity of combretastatin-A4. Int J Oncol 19:821–825PubMedGoogle Scholar
  71. Guidi AJ, Fischer L, Harris JR, Schnitt SJ (1994) Microvessel density and distribution in ductal carcinoma in situ of the breast. J Natl Cancer Inst 86:614–619PubMedGoogle Scholar
  72. Gutheil JC, Campbell TN, Pierce PR, Watkins JD, Huse WD, Bodkin DJ, Cheresh DA (2000) Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 6:3056–3061PubMedGoogle Scholar
  73. Harpole DH Jr, Richards WG, Herndon JE, Sugarbaker DJ (1996) Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer. Ann Thorac Surg 61:1470–1476CrossRefPubMedGoogle Scholar
  74. Hasan J, Byers R, Jayson GC (2002) Intra-tumoural microvessel density in human solid tumours. Br J Cancer 86:1566–1577CrossRefPubMedGoogle Scholar
  75. Hawighorst H, Knapstein PG, Weikel W, Knopp MV, Zuna I, Knof A, Brix G, Schaeffer U, Wilkens C, Schoenberg SO, Essig M, Vaupel P, van Kaick G (1997) Angiogenesis of uterine cervical carcinoma: characterization by pharmacokinetic magnetic resonance parameters and histological microvessel density with correlation to lymphatic involvement. Cancer Res 57:4777–4786PubMedGoogle Scholar
  76. Hawighorst H, Libicher M, Knopp MV, Moehler T, Kauffmann GW, Kaick G (1999) Evaluation of angiogenesis and perfusion of bone marrow lesions: role of semiquantitative and quantitative dynamic MRI. J Magn Reson Imaging 10:286–294CrossRefPubMedGoogle Scholar
  77. Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C, Madden T, Davis DW, McConkey DJ, O'Reilly MS, Ellis LM, Pluda J, Hong WK, Abbruzzese JL (2002a) Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 20:3792–3803CrossRefPubMedGoogle Scholar
  78. Herbst RS, Madden TL, Tran HT, Blumenschein GR Jr, Meyers CA, Seabrooke LF, Khuri FR, Puduvalli VK, Allgood V, Fritsche HA Jr, Hinton L, Newman RA, Crane EA, Fossella FV, Dordal M, Goodin T, Hong WK (2002b) Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. J Clin Oncol 20:4440–4447CrossRefPubMedGoogle Scholar
  79. Herbst RS, Mullani NA, Davis DW, Hess KR, McConkey DJ, Charnsangavej C, O'Reilly MS, Kim HW, Baker C, Roach J, Ellis LM, Rashid A, Pluda J, Bucana C, Madden TL, Tran HT, Abbruzzese JL (2002c) Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 20:3804–3814CrossRefPubMedGoogle Scholar
  80. Hidalgo M, Eckhardt SG (2001) Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 93:178–193CrossRefPubMedGoogle Scholar
  81. Hlatky L, Hahnfeldt P, Folkman J (2002) Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 94:883–893PubMedGoogle Scholar
  82. Hoekstra CJ, Stroobants SG, Hoekstra OS, Smit EF, Vansteenkiste JF, Lammertsma AA (2002) Measurement of perfusion in stage IIIA-N2 non-small cell lung cancer using H(2)(15)O and positron emission tomography. Clin Cancer Res 8:2109–2115PubMedGoogle Scholar
  83. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ (1999) Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284:1994–1998CrossRefPubMedGoogle Scholar
  84. Hurwitz H, Holden SN, Eckhardt SG (2002) Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signaling in patients with solid tumors. Proc ASCO 21, 82a, abstractGoogle Scholar
  85. Hurwitz H, Fehrenbacher L, Cartwright T, Hainsworth J, Heim W, Berlin J, Griffing S, Novotny W, Holmgren E, Kabbinavar F (2003) Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc ASCO 22, 3646, abstractGoogle Scholar
  86. Jayson GC, Zweit J, Jackson A, Mulatero C, Julyan P, Ranson M, Broughton L, Wagstaff J, Hakannson L, Groenewegen G, Bailey J, Smith N, Hastings D, Lawrance J, Haroon H, Ward T, McGown AT, Tang M, Levitt D, Marreaud S, Lehmann FF, Herold M, Zwierzina H (2002a) Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 94:1484–1493PubMedGoogle Scholar
  87. Jayson GC, Zweit J, Jackson A, Mulatero C, Julyan P, Ranson M, Broughton L, Wagstaff J, Hakannson L, Groenewegen G, Bailey J, Smith N, Hastings D, Lawrance J, Haroon H, Ward T, McGown AT, Tang M, Levitt D, Marreaud S, Lehmann FF, Herold M, Zwierzina H (2002b) Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 94:1484–1493PubMedGoogle Scholar
  88. Kanthou C, Tozer GM (2002) The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 99:2060–2069CrossRefPubMedGoogle Scholar
  89. Kawaguchi T, Yamamoto S, Kudoh S, Goto K, Wakasa K, Sakurai M (1997) Tumor angiogenesis as a major prognostic factor in stage I lung adenocarcinoma. Anticancer Res 17:3743–3746PubMedGoogle Scholar
  90. Keith RL, Miller YE, Gemmill RM, Drabkin HA, Dempsey EC, Kennedy TC, Prindiville S, Franklin WA (2000) Angiogenic squamous dysplasia in bronchi of individuals at high risk for lung cancer. Clin Cancer Res 6:1616–1625PubMedGoogle Scholar
  91. Kerbel RS (2000) Tumor angiogenesis: past, present and the near future. Carcinogenesis 21:505–515CrossRefPubMedGoogle Scholar
  92. Khan AW, Dhillon AP, Hutchins R, Abraham A, Shah SR, Snooks S, Davidson BR (2002) Prognostic significance of intratumoural microvessel density (IMD) in resected pancreatic and ampullary cancers to standard histopathological variables and survival. Eur J Surg Oncol 28:637–644CrossRefPubMedGoogle Scholar
  93. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841–844CrossRefPubMedGoogle Scholar
  94. Kim SW, Park SS, Ahn SJ, Chung KW, Moon WK, Im JG, Yeo JS, Chung JK, Noh DY (2002) Identification of angiogenesis in primary breast carcinoma according to the image analysis. Breast Cancer Res Treat 74:121–129CrossRefPubMedGoogle Scholar
  95. Kossakowska AE, Huchcroft SA, Urbanski SJ, Edwards DR (1996) Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphomas in humans. Br J Cancer 73:1401–1408PubMedGoogle Scholar
  96. Kostakoglu L, Goldsmith SJ (2003) 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J Nucl Med 44:224–239PubMedGoogle Scholar
  97. Koukourakis MI, Giatromanolaki A, O'Byrne KJ, Comley M, Whitehouse RM, Talbot DC, Gatter KC, Harris AL (1997) Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer. Br J Cancer 75:477–481PubMedGoogle Scholar
  98. Koukourakis MI, Giatromanolaki A, Thorpe PE, Brekken RA, Sivridis E, Kakolyris S, Georgoulias V, Gatter KC, Harris AL (2000) Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res 60:3088–3095PubMedGoogle Scholar
  99. Landuyt W, Ahmed B, Nuyts S, Theys J, Op dB, Rijnders A, Anne J, van Oosterom A, Van Den BW, Lambin P (2001) In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. Int J Radiat Oncol Biol Phys 49:443–450CrossRefPubMedGoogle Scholar
  100. Lee JS, Kim HS, Jung JJ, Lee MC, Park CS (2002) Angiogenesis, cell proliferation and apoptosis in progression of cervical neoplasia. Anal Quant Cytol Histol 24:103–113PubMedGoogle Scholar
  101. Leong-Poi H, Christiansen JP, Klibanov AL, Kaul S, Lindner JR (2003) Noninvasive assessment of angiogenesis by contrast ultrasound imaging with microbubbles targeted to alpha-V integrins. J Am Coll Cardiol 41:430–431CrossRefGoogle Scholar
  102. Levitt NC, Eskens FA, O'Byrne KJ, Propper DJ, Denis LJ, Owen SJ, Choi L, Foekens JA, Wilner S, Wood JM, Nakajima M, Talbot DC, Steward WP, Harris AL, Verweij J (2001) Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. Clin Cancer Res 7:1912–1922PubMedGoogle Scholar
  103. Li X, Liu X, Wang J, Wang Z, Jiang W, Reed E, Zhang Y, Liu Y, Li QQ (2003) Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells. Anticancer Res 23:2481–2487PubMedGoogle Scholar
  104. Liekens S, de Clercq E, Neyts J (2001) Angiogenesis: regulators and clinical applications. Biochem Pharmacol 61:253–270CrossRefPubMedGoogle Scholar
  105. Lozonschi L, Sunamura M, Kobari M, Egawa S, Ding L, Matsuno S (1999) Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. Cancer Res 59:1252–1258PubMedGoogle Scholar
  106. Lucchi M, Mussi A, Fontanini G, Faviana P, Ribechini A, Angeletti CA (2002) Small cell lung carcinoma (SCLC): the angiogenic phenomenon. Eur J Cardiothorac Surg 21:1105–1110CrossRefPubMedGoogle Scholar
  107. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, Wu Y, Hicklin D, Zhu Z, Hackett NR, Crystal RG, Moore MA, Hajjar KA, Manova K, Benezra R, Rafii S (2001) Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7:1194–1201CrossRefPubMedGoogle Scholar
  108. Macchiarini P, Fontanini G, Hardin MJ, Squartini F, Angeletti CA (1992) Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet 340:145–146CrossRefPubMedGoogle Scholar
  109. Macluskey M, Baillie R, Chandrachud LM, Pendleton N, Schor AM (2000) High levels of apoptosis are associated with improved survival in non-small cell lung cancer. Anticancer Res 20:2123–2128PubMedGoogle Scholar
  110. Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, Bertolini F (2001) Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 97:3658–3661CrossRefPubMedGoogle Scholar
  111. Marimastat: BB 2516, TA 2516 (2003) Drugs R D 4:198–203Google Scholar
  112. Massi D, Franchi A, Borgognoni L, Paglierani M, Reali UM, Santucci M (2002) Tumor angiogenesis as a prognostic factor in thick cutaneous malignant melanoma. A quantitative morphologic analysis. Virchows Arch 440:22–28CrossRefPubMedGoogle Scholar
  113. Matsuyama K, Chiba Y, Sasaki M, Tanaka H, Muraoka R, Tanigawa N (1998) Tumor angiogenesis as a prognostic marker in operable non-small cell lung cancer. Ann Thorac Surg 65:1405–1409CrossRefPubMedGoogle Scholar
  114. Matsuyama W, Hashiguchi T, Mizoguchi A, Iwami F, Kawabata M, Arimura K, Osame M (2000) Serum levels of vascular endothelial growth factor dependent on the stage progression of lung cancer. Chest 118:948–951CrossRefPubMedGoogle Scholar
  115. Mattern J, Koomagi R, Volm M (1996) Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer 73:931–934PubMedGoogle Scholar
  116. Mattern J, Stammler G, Koomagi R, Wallwiener D, Kaufmann M, Volm M (1997) Association of vascular endothelial growth factor expression with tumor cell proliferation in ovarian carcinoma. Anticancer Res 17:621–624PubMedGoogle Scholar
  117. McCulloch P, Choy A, Martin L (1995) Association between tumour angiogenesis and tumour cell shedding into effluent venous blood during breast cancer surgery. Lancet 346:1334–1335CrossRefPubMedGoogle Scholar
  118. Meeson AP, Argilla M, Ko K, Witte L, Lang RA (1999) VEGF deprivation-induced apoptosis is a component of programmed capillary regression. Development 126:1407–1415PubMedGoogle Scholar
  119. Miettinen M (1993) Immunohistochemistry in tumour diagnosis. Ann Med 25:221–233PubMedGoogle Scholar
  120. Miles KA, Charnsangavej C, Lee FT, Fishman EK, Horton K, Lee TY (2000) Application of CT in the investigation of angiogenesis in oncology. Acad Radiol 7:840–850PubMedGoogle Scholar
  121. Moore BB, Arenberg DA, Addison CL, Keane MP, Strieter RM (1998) Tumor angiogenesis is regulated by CXC chemokines. J Lab Clin Med 132:97–103CrossRefPubMedGoogle Scholar
  122. Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, Horsfield MA, Mross K, Ball HA, Lee L, Mietlowski W, Fuxuis S, Unger C, O'Byrne K, Henry A, Cherryman GR, Laurent D, Dugan M, Marme D, Steward WP (2003) Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21:3955–3964CrossRefPubMedGoogle Scholar
  123. Morinaga Y, Suga Y, Ehara S, Harada K, Nihei Y, Suzuki M (2003) Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo. Cancer Sci 94:200–204CrossRefPubMedGoogle Scholar
  124. Mountain CF (2000) The international system for staging lung cancer. Semin Surg Oncol 18:106–115CrossRefPubMedGoogle Scholar
  125. Mountain CF, Hermes KE (2003) Surgical treatment of lung cancer. Past and present. Methods Mol Med 75:453–487PubMedGoogle Scholar
  126. Murphy G, Stanton H, Cowell S, Butler G, Knauper V, Atkinson S, Gavrilovic J (1999) Mechanisms for pro matrix metalloproteinase activation. APMIS 107:38–44PubMedGoogle Scholar
  127. Neeman M, Dafni H, Bukhari O, Braun RD, Dewhirst MW (2001) In vivo BOLD contrast MRI mapping of subcutaneous vascular function and maturation: validation by intravital microscopy. Magn Reson Med 45:887–898CrossRefPubMedGoogle Scholar
  128. Nilsson F, Kosmehl H, Zardi L, Neri D (2001) Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 61:711–716PubMedGoogle Scholar
  129. O'Byrne KJ, Koukourakis MI, Giatromanolaki A, Cox G, Turley H, Steward WP, Gatter K, Harris AL (2000) Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer 82:1427–1432PubMedGoogle Scholar
  130. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315–328CrossRefPubMedGoogle Scholar
  131. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277–285CrossRefPubMedGoogle Scholar
  132. Ohta Y, Endo Y, Tanaka M, Shimizu J, Oda M, Hayashi Y, Watanabe Y, Sasaki T (1996) Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer. Clin Cancer Res 2:1411–1416PubMedGoogle Scholar
  133. Ohta Y, Ohta N, Tamura M, Wu J, Tsunezuka Y, Oda M, Watanabe G (2002) Vascular endothelial growth factor expression in airways of patients with lung cancer: a possible diagnostic tool of responsive angiogenic status on the host side. Chest 121:1624–1627CrossRefPubMedGoogle Scholar
  134. Oshika Y, Nakamura M, Tokunaga T, Ohnishi Y, Abe Y, Tsuchida T, Tomii Y, Kijima H, Yamazaki H, Ozeki Y, Tamaoki N, Ueyama Y (2000) Ribozyme approach to downregulate vascular endothelial growth factor (VEGF) 189 expression in non-small cell lung cancer (NSCLC). Eur J Cancer 36:2390–2396CrossRefPubMedGoogle Scholar
  135. Paku S (1998) Current concepts of tumor-induced angiogenesis. Pathol Oncol Res 4:62–75PubMedGoogle Scholar
  136. Papamichael D (2001) Prognostic role of angiogenesis in colorectal cancer. Anticancer Res 21:4349–4353PubMedGoogle Scholar
  137. Papapetropoulos A, Garcia-Cardena G, Dengler TJ, Maisonpierre PC, Yancopoulos GD, Sessa WC (1999) Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Lab Invest 79:213–223PubMedGoogle Scholar
  138. Pastorino U, Andreola S, Tagliabue E, Pezzella F, Incarbone M, Sozzi G, Buyse M, Menard S, Pierotti M, Rilke F (1997) Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol 15:2858–2865PubMedGoogle Scholar
  139. Pavco PA, Bouhana KS, Gallegos AM, Agrawal A, Blanchard KS, Grimm SL, Jensen KL, Andrews LE, Wincott FE, Pitot PA, Tressler RJ, Cushman C, Reynolds MA, Parry TJ (2000) Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin Cancer Res 6:2094–2103PubMedGoogle Scholar
  140. Peters-Engl C, Medl M, Mirau M, Wanner C, Bilgi S, Sevelda P, Obermair A (1998) Color-coded and spectral Doppler flow in breast carcinomas — relationship with the tumor microvasculature. Breast Cancer Res Treat 47:83–89CrossRefPubMedGoogle Scholar
  141. Pezzella F, Pastorino U, Tagliabue E, Andreola S, Sozzi G, Gasparini G, Menard S, Gatter KC, Harris AL, Fox S, Buyse M, Pilotti S, Pierotti M, Rilke F (1997) Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol 151:1417–1423PubMedGoogle Scholar
  142. Philpott M, Baguley BC, Ching LM (1995) Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 36:143–148PubMedGoogle Scholar
  143. Poulaki V (2002) BMS-275291. Bristol-Myers Squibb. Curr Opin Invest Drugs 3:500–504Google Scholar
  144. Raymond E, Faivre S, Vera K, Delbaldo C, Robert C, Brega N, Achour A, Massimini G, Schigalla P, Armand JP (2002) First results of a phase I and pharmacokinetic study of SU011248, a novel oral anti-angiogenic agent, in patients with advanced solid tumours. Eur J Cancer 38[Suppl 7]:17CrossRefPubMedGoogle Scholar
  145. Rewcastle GW, Atwell GJ, Li ZA, Baguley BC, Denny WA (1991) Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J Med Chem 34:217–222CrossRefPubMedGoogle Scholar
  146. Richards MA, Stockton D, Babb P, Coleman MP (2000) How many deaths have been avoided through improvements in cancer survival? BMJ 320:895–898CrossRefPubMedGoogle Scholar
  147. Risau W (1997) Mechanisms of angiogenesis. Nature 386:671–674CrossRefPubMedGoogle Scholar
  148. Robinson SP, Howe FA, Griffiths JR (1995) Noninvasive monitoring of carbogen-induced changes in tumor blood flow and oxygenation by functional magnetic resonance imaging. Int J Radiat Oncol Biol Phys 33:855–859CrossRefPubMedGoogle Scholar
  149. Ruotsalainen T, Joensuu H, Mattson K, Salven P (2002) High pretreatment serum concentration of basic fibroblast growth factor is a predictor of poor prognosis in small cell lung cancer. Cancer Epidemiol Biomarkers Prev 11:1492–1495PubMedGoogle Scholar
  150. Salven P, Ruotsalainen T, Mattson K, Joensuu H (1998) High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer 79:144–146CrossRefPubMedGoogle Scholar
  151. Schiller JH, Bittner G (1999) Potentiation of platinum antitumor effects in human lung tumor xenografts by the angiogenesis inhibitor squalamine: effects on tumor neovascularization. Clin Cancer Res 5:4287–4294PubMedGoogle Scholar
  152. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983–985PubMedGoogle Scholar
  153. Shepherd FA, Sridhar SS (2003) Angiogenesis inhibitors under study for the treatment of lung cancer. Lung Cancer 41[Suppl 1]:S63–S72CrossRefPubMedGoogle Scholar
  154. Shi W, Siemann DW (2002) Inhibition of renal cell carcinoma angiogenesis and growth by antisense oligonucleotides targeting vascular endothelial growth factor. Br J Cancer 87:119–126CrossRefPubMedGoogle Scholar
  155. Siegfried JM, Weissfeld LA, Luketich JD, Weyant RJ, Gubish CT, Landreneau RJ (1998) The clinical significance of hepatocyte growth factor for non-small cell lung cancer. Ann Thorac Surg 66:1915–1918CrossRefPubMedGoogle Scholar
  156. Siemann DW, Shi W (2003) Targeting the tumor blood vessel network to enhance the efficacy of radiation therapy. Semin Radiat Oncol 13:53–61CrossRefPubMedGoogle Scholar
  157. Siemann DW, Mercer E, Lepler S, Rojiani AM (2002) Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 99:1–6CrossRefPubMedGoogle Scholar
  158. Sills AK Jr, Williams JI, Tyler BM, Epstein DS, Sipos EP, Davis JD, McLane MP, Pitchford S, Cheshire K, Gannon FH, Kinney WA, Chao TL, Donowitz M, Laterra J, Zasloff M, Brem H (1998) Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature. Cancer Res 58:2784–2792PubMedGoogle Scholar
  159. Sin N, Meng L, Wang MQ, Wen JJ, Bornmann WG, Crews CM (1997) The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci USA 94:6099–6103CrossRefPubMedGoogle Scholar
  160. Smylie M, Mercier R, Aboulafia D et al (2001) Phase III study of the matrix metalloproteinase (MMP) inhibitor Prinomastat in patients having advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 20-307aGoogle Scholar
  161. Solorzano CC, Baker CH, Bruns CJ, Killion JJ, Ellis LM, Wood J, Fidler IJ (2001) Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother Radiopharm 16:359–370CrossRefPubMedGoogle Scholar
  162. St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein B, Kinzler KW (2000) Genes expressed in human tumor endothelium. Science 289:1197–1202CrossRefPubMedGoogle Scholar
  163. Steward WP (1999) Marimastat (BB2516): current status of development. Cancer Chemother Pharmacol 43[Suppl]:S56–S60CrossRefPubMedGoogle Scholar
  164. Strizzi L, Vianale G, Catalano A, Muraro R, Mutti L, Procopio A (2001) Basic fibroblast growth factor in mesothelioma pleural effusions: correlation with patient survival and angiogenesis. Int J Oncol 18:1093–1098PubMedGoogle Scholar
  165. Strobel D, Krodel U, Martus P, Hahn EG, Becker D (2000) Clinical evaluation of contrast-enhanced color Doppler sonography in the differential diagnosis of liver tumors. J Clin Ultrasound 28:1–13CrossRefPubMedGoogle Scholar
  166. Su MY, Cheung YC, Fruehauf JP, Yu H, Nalcioglu O, Mechetner E, Kyshtoobayeva A, Chen SC, Hsueh S, McLaren CE, Wan YL (2003) Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancer. J Magn Reson Imaging 18:467–477CrossRefPubMedGoogle Scholar
  167. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM (1995) Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 55:3964–3968PubMedGoogle Scholar
  168. Takigawa N, Segawa Y, Fujimoto N, Hotta K, Eguchi K (1998) Elevated vascular endothelial growth factor levels in sera of patients with lung cancer. Anticancer Res 18:1251–1254PubMedGoogle Scholar
  169. Tamura M, Ohta Y, Kajita T, Kimura K, Go T, Oda M, Nakamura H, Watanabe G (2001) Plasma VEGF concentration can predict the tumor angiogenic capacity in non-small cell lung cancer. Oncol Rep 8:1097–1102PubMedGoogle Scholar
  170. Tamura M, Ohta Y, Nakamura H, Oda M, Watanabe G (2002) Diagnostic value of plasma vascular endothelial growth factor as a tumor marker in patients with non-small cell lung cancer. Int J Biol Markers 17:275–279PubMedGoogle Scholar
  171. Tanaka F, Ishikawa S, Yanagihara K, Miyahara R, Kawano Y, Li M, Otake Y, Wada H (2002) Expression of angiopoietins and its clinical significance in non-small cell lung cancer. Cancer Res 62:7124–7129PubMedGoogle Scholar
  172. Tanigawa N, Amaya H, Matsumura M, Shimomatsuya T, Horiuchi T, Muraoka R, Iki M (1996) Extent of tumor vascularization correlates with prognosis and hematogenous metastasis in gastric carcinomas. Cancer Res 56:2671–2676PubMedGoogle Scholar
  173. Teicher BA, Holden SA, Ara G, Sotomayor EA, Huang ZD, Chen YN, Brem H (1994) Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int J Cancer 57:920–925PubMedGoogle Scholar
  174. Teicher BA, Williams JI, Takeuchi H, Ara G, Herbst RS, Buxton D (1998) Potential of the aminosterol, squalamine in combination therapy in the rat 13,762 mammary carcinoma and the murine Lewis lung carcinoma. Anticancer Res 18:2567–2573PubMedGoogle Scholar
  175. Thomas JP, Arzoomanian RZ, Alberti D, Marnocha R, Lee F, Friedl A, Tutsch K, Dresen A, Geiger P, Pluda J, Fogler W, Schiller JH, Wilding G (2003) Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 21:223–231CrossRefPubMedGoogle Scholar
  176. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, Port RE, Taylor J, Weisskoff RM (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10:223–232CrossRefPubMedGoogle Scholar
  177. Toi M, Kashitani J, Tominaga T (1993) Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int J Cancer 55:371–374PubMedGoogle Scholar
  178. Trepel M, Arap W, Pasqualini R (2000) Exploring vascular heterogeneity for gene therapy targeting. Gene Ther 7:2059–2060CrossRefPubMedGoogle Scholar
  179. Tuder RM, Cool CD, Yeager M, Taraseviciene-Stewart L, Bull TM, Voelkel NF (2001) The pathobiology of pulmonary hypertension. Endothelium. Clin Chest Med 22:405–418CrossRefPubMedGoogle Scholar
  180. Ueno K, Inoue Y, Kawaguchi T, Hosoe S, Kawahara M (2001) Increased serum levels of basic fibroblast growth factor in lung cancer patients: relevance to response of therapy and prognosis. Lung Cancer 31:213–219CrossRefPubMedGoogle Scholar
  181. Van der Woude HJ, Bloem JL, van Oostayen JA, Nooy MA, Taminiau AH, Hermans J, Reynierse M, Hogendoorn PC (1995) Treatment of high-grade bone sarcomas with neoadjuvant chemotherapy: the utility of sequential color Doppler sonography in predicting histopathologic response. AJR Am J Roentgenol 165:125–133PubMedGoogle Scholar
  182. Veenendaal LM, Jin H, Ran S, Cheung L, Navone N, Marks JW et al (2002) In vitro an in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. Proc Natl Acad Sci USA 99:7866–7871CrossRefPubMedGoogle Scholar
  183. Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezzella F, Viale G, Weidner N, Harris AL, Dirix LY (1996) Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 32A:2474–2484CrossRefPubMedGoogle Scholar
  184. Vihinen P, Kahari VM (2002) Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 99:157–166CrossRefPubMedGoogle Scholar
  185. Volm M, Koomagi R, Mattern J (1997a) Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int J Cancer 74:64–68CrossRefPubMedGoogle Scholar
  186. Volm M, Koomagi R, Mattern J, Stammler G (1997b) Prognostic value of basic fibroblast growth factor and its receptor (FGFR-1) in patients with non-small cell lung carcinomas. Eur J Cancer 33:691–693CrossRefPubMedGoogle Scholar
  187. Watanabe Y, Dvorak HF (1997) Vascular permeability factor/ vascular endothelial growth factor inhibits anchorage-disruption-induced apoptosis in microvessel endothelial cells by inducing scaffold formation. Exp Cell Res 233:340–349CrossRefPubMedGoogle Scholar
  188. Webb NJ, Bottomley MJ, Watson CJ, Brenchley PE (1998) Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin Sci (Lond) 94:395–404PubMedGoogle Scholar
  189. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J (1993) Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143:401–409PubMedGoogle Scholar
  190. Weir HK, Thun MJ, Hankey BF, Ries LA, Howe HL, Wingo PA, Jemal A, Ward E, Anderson RN, Edwards BK (2003) Annual report to the nation on the status of cancer 1975–2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 95:1276–1299PubMedGoogle Scholar
  191. Witte L, Hicklin DJ, Zhu Z, Pytowski B, Kotanides H, Rockwell P, Bohlen P (1998) Monoclonal antibodies targeting the VEGF receptor-2 (Flk 1/KDR) as an antiangiogenic therapeutic strategy. Cancer Metastasis Rev 17:155–161CrossRefPubMedGoogle Scholar
  192. Wong MP, Chan SY, Fu KH, Leung SY, Cheung N, Yuen ST, Chung LP (2000) The angiopoietins, tie2 and vascular endothelial growth factor are differentially expressed in the transformation of normal lung to non-small cell lung carcinomas. Lung Cancer 29:11–22CrossRefPubMedGoogle Scholar
  193. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rosel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F (2000) PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60:2178–2189PubMedGoogle Scholar
  194. World Health Organization (1979) WHO Handbook for Reporting Results of Cancer Treatment. World Health Organization, Geneva, SwitzerlandGoogle Scholar
  195. Yamashita J, Ogawa M, Abe M, Nishida M (1999) Platelet-derived endothelial cell growth factor/thymidine phosphorylase concentrations differ in small cell and non-small cell lung cancer. Chest 116:206–211CrossRefPubMedGoogle Scholar
  196. Yamazaki K, Abe S, Takekawa H, Sukoh N, Watanabe N, Ogura S, Nakajima I, Isobe H, Inoue K, Kawakami Y (1994) Tumor angiogenesis in human lung adenocarcinoma. Cancer 74:2245–2250PubMedGoogle Scholar
  197. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427–434CrossRefGoogle Scholar
  198. Yoon SS, Eto H, Lin CM, Nakamura H, Pawlik TM, Song SU, Tanabe KK (1999) Mouse endostatin inhibits the formation of lung and liver metastases. Cancer Res 59:6251–6256PubMedGoogle Scholar
  199. Yuan A, Yu CJ, Chen WJ, Lin FY, Kuo SH, Luh KT, Yang PC (2000) Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer. Int J Cancer 89:475–483CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • Dietmar W. Siemann
    • 1
  • Susan M. Galbraith
    • 2
  • Wenyin Shi
    • 1
  1. 1.Department of Radiation Oncology, Shands Cancer CenterUniversity of FloridaGainesvilleUSA
  2. 2.Bristol-Myers Squibb Company, Clinical DiscoveryPharmaceutical Research InstitutePrincetonUSA

Personalised recommendations